Hester Biosciences has received the WHO GMP Certification for poultry vaccines. This certification would help the company in hastening the registration process in many countries, as well as in opening the registration doors in the regulated markets.
Besides, the company is also in the process of launching its locally produced Bivalent Marek’s Disease Live vaccine containing HVT & SB1 strains. Currently, trails are being conducted. The market for this vaccine is approximately Rs 30 crore.
At present, nearly 50% of the vaccine requirement is imported. Hester’s local production of this vaccine will be an import replacement, besides providing a cost advantage to the Indian poultry farmers. Hester expects an overall growth of 25% in sales in this financial year, over last year.
